Publicaciones en colaboración con investigadores/as de Azienda Ospedaliero-Universitaria Careggi (9)

2024

  1. In vitro activity of ozenoxacin against Staphylococcus aureus and Streptococcus pyogenes clinical isolates recovered in a worldwide multicentre study (2020-2022)

    JAC-Antimicrobial Resistance, Vol. 6, Núm. 3

2022

  1. Isothermal microcalorimetry vs checkerboard assay to evaluate in-vitro synergism of meropenem–amikacin and meropenem–colistin combinations against multi-drug-resistant Gram-negative pathogens

    International Journal of Antimicrobial Agents, Vol. 60, Núm. 4

2021

  1. Antimicrobial resistance research in a post-pandemic world: Insights on antimicrobial resistance research in the COVID-19 pandemic

    Journal of Global Antimicrobial Resistance, Vol. 25, pp. 5-7

  2. Effective antimicrobial combination in vivo treatment predicted with microcalorimetry screening

    The Journal of antimicrobial chemotherapy, Vol. 76, Núm. 4, pp. 1001-1009

  3. Key considerations on the potential impacts of the COVID-19 pandemic on antimicrobial resistance research and surveillance

    Transactions of the Royal Society of Tropical Medicine and Hygiene, Vol. 115, Núm. 10, pp. 1122-1129

2020

  1. Isothermal microcalorimetry minimal inhibitory concentration testing in extensively drug resistant Gram-negative bacilli: a multicentre study

    Clinical Microbiology and Infection, Vol. 26, Núm. 10, pp. 1413.e1-1413.e7

2017

  1. Etestw versus broth microdilution for ceftaroline MIC determination with Staphylococcus aureus: Results from PREMIUM, a European multicentre study

    Journal of Antimicrobial Chemotherapy, Vol. 72, Núm. 2, pp. 431-436

  2. Occurrence of carbapenemase-producing Klebsiella pneumoniae and Escherichia coli in the European survey of carbapenemase-producing Enterobacteriaceae (EuSCAPE): a prospective, multinational study

    The Lancet Infectious Diseases, Vol. 17, Núm. 2, pp. 153-163

2015

  1. In vitro activity of ceftazidime, ceftaroline and aztreonam alone and in combination with avibactam against European Gram-negative and Gram-positive clinical isolates

    International Journal of Antimicrobial Agents, Vol. 45, Núm. 6, pp. 641-646